137 related articles for article (PubMed ID: 25700368)
1. The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.
Pekarsky Y; Drusco A; Kumchala P; Croce CM; Zanesi N
Gene Expr; 2015; 16(3):129-35. PubMed ID: 25700368
[TBL] [Abstract][Full Text] [Related]
2. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
3. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
4. The TCL1 mouse as a model for chronic lymphocytic leukemia.
Hamblin TJ
Leuk Res; 2010 Feb; 34(2):135-6. PubMed ID: 19726084
[TBL] [Abstract][Full Text] [Related]
5. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
6. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
[TBL] [Abstract][Full Text] [Related]
7. The role of TCL1 in human T-cell leukemia.
Pekarsky Y; Hallas C; Croce CM
Oncogene; 2001 Sep; 20(40):5638-43. PubMed ID: 11607815
[TBL] [Abstract][Full Text] [Related]
8. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Gorgun G; Ramsay AG; Holderried TA; Zahrieh D; Le Dieu R; Liu F; Quackenbush J; Croce CM; Gribben JG
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6250-5. PubMed ID: 19332800
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.
Hoyer KK; French SW; Turner DE; Nguyen MT; Renard M; Malone CS; Knoetig S; Qi CF; Su TT; Cheroutre H; Wall R; Rawlings DJ; Morse HC; Teitell MA
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14392-7. PubMed ID: 12381789
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.
Kriss CL; Pinilla-Ibarz JA; Mailloux AW; Powers JJ; Tang CH; Kang CW; Zanesi N; Epling-Burnette PK; Sotomayor EM; Croce CM; Del Valle JR; Hu CC
Blood; 2012 Aug; 120(5):1027-38. PubMed ID: 22692508
[TBL] [Abstract][Full Text] [Related]
11. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
12. Deregulated expression of TCL1 causes T cell leukemia in mice.
Virgilio L; Lazzeri C; Bichi R; Nibu K; Narducci MG; Russo G; Rothstein JL; Croce CM
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3885-9. PubMed ID: 9520462
[TBL] [Abstract][Full Text] [Related]
13. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
14. The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.
Holroyd A; Cross NC; Macdonald DH
Leuk Res; 2011 Oct; 35(10):1279-85. PubMed ID: 21722956
[TBL] [Abstract][Full Text] [Related]
15. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.
Herling M; Patel KA; Hsi ED; Chang KC; Rassidakis GZ; Ford R; Jones D
Am J Surg Pathol; 2007 Jul; 31(7):1123-9. PubMed ID: 17592280
[TBL] [Abstract][Full Text] [Related]
16. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
[TBL] [Abstract][Full Text] [Related]
17. Tcl1 as a model for lymphomagenesis.
Pekarsky Y; Zanesi N; Aqeilan R; Croce CM
Hematol Oncol Clin North Am; 2004 Aug; 18(4):863-79, ix. PubMed ID: 15325703
[TBL] [Abstract][Full Text] [Related]
18. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer JP; Heyder C; Denk U; Kocher T; Holler C; Trapin D; Asslaber D; Tinhofer I; Greil R; Egle A
Leukemia; 2011 Sep; 25(9):1452-8. PubMed ID: 21606964
[TBL] [Abstract][Full Text] [Related]
19. [Research Progress in Transgenic Animal Models of Chronic Lymphocytic Leukemia -Review].
Wu FT; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):259-263. PubMed ID: 28245413
[TBL] [Abstract][Full Text] [Related]
20. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
